Searched for
LUPIN LABORATORIES
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- More women CXOs join India’s million-dollar pay club as domestic firms lead compensation growthNine women now earn over one million dollars annually as C-suite executives. Domestic companies are leading this rise, reflecting a focus o...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Small & midcaps rally! Wockhardt, Coforge, other stocks surge up to 14%. Do you own any?Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- GLP-1 impact: Jefferies sees these 3 stocks as winners in the race for Ozempic, Wegovy genericsIndian drug makers are launching affordable generic Semaglutide, the active ingredient in popular weight-loss drugs. Sun Pharma, Lupin, and...
- Natco Pharma, 3 other pharma stocks decline up to 2.5% after important inspections at their units. Do you own?Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at ...
- Lupin, Glenmark Pharma, 7 BSE Healthcare stocks which hit 52-week high on WednesdayThe data was sourced from BSE at 2.50 pm, and the updates from the real-time data could come with a lag. The below data also pertains only ...
- Lupin opens main reference lab in Kolkata for expansion in east IndiaThe company offers a comprehensive range of diagnostics services to doctors, patients and consumers. Some of its key consumer-centric featu...
- Lupin announces launch of its diagnostics businessCommenting on the development, Lupin Managing Director Nilesh Gupta said, "combining decades of experience and knowledge in the field of th...
- Lupin gets USFDA nod to market cancer drugThe approved product is indicated for cleansing of the colon in preparation of colonoscopy in adults. Suprep Bowel Prep Kit had US sales of...
- Lupin inks licensing pact with US firm Romark Laboratories for diarrhoea drugLupin has inked a licensing pact with US-based pharma firm Romark Laboratories to market the latter's diarrhoea treatment drug 'Alinia'.
- Bullish on Lupin: Ashwani GujralLupin obviously is outperforming and likely to get up to Rs 510. Ranbaxy has also moved into some support zone.
- Lupin files second suit against RanbaxyMumbai-based drugmaker Lupin has filed a second suit in the US against Ranbaxy Laboratories to prevent the country’s largest drugmaker from...
- Lupin shares drop by 5 pc on BSEShares of pharmaceutical firm Lupin fell by nearly five per cent in early trade on the Bombay Stock Exchange, a day after EU said it has in...
- French co buys IP rights from LupinThe Mumbai-based pharma co will receive 20 mn euros from Servier Laboratories for its process patents.
Load More
